US climate favours biosimilars, but legislation will take some time
This article was originally published in Scrip
The new political environment in Washington favours the approval of a biosimilars pathway, but getting the legislation through is still likely to be a long haul.
You may also be interested in...
The Conservative Party's victory in the UK general election means the Brexit withdrawal deal will be able to pass. The UK will leave the EU by 31 January and enter a transition period during which medicines regulation will remain broadly unchanged.
Health ministers have called for more action on access to medicines, including a new EU work agenda, rebuilding Europe’s manufacturing capabilities, further action on pricing, and greater leeway for member states to mitigate drug shortages by restricting parallel exports.